Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease – a CARE CR study

Simon Nichols1, Alasdair F. O’Doherty2, Claire Taylor3, Andrew L. Clark4, Sean Carroll5 and Lee Ingle5

1Centre for Sports and Exercise Science, Sheffield Hallam University, Sheffield, 2Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle-Upon-Tyne, 3Carnegie School of Sport, Leeds Beckett University, Leeds, 4Academic Cardiology, Castle Hill Hospital, Cottingham, and 5Sport Health Science, University of Hull, Hull, UK

Summary

Background In patients with chronic heart failure, there is a positive linear relationship between skeletal muscle mass (SMM) and peak oxygen consumption (VO2peak); an independent predictor of all-cause mortality. We investigated the association between SMM and VO2peak in patients with coronary heart disease (CHD) without a diagnosis of heart failure.

Methods Male patients with CHD underwent maximal cardiopulmonary exercise testing and dual X-ray absorptiometry assessment. VO2peak, the ventilatory anaerobic threshold and peak oxygen pulse were calculated. SMM was expressed as appendicular lean mass (lean mass in both arms and legs) and reported as skeletal muscle index (SMI; kg m⁻²), and as a proportion of total body mass (appendicular skeletal mass [ASM%]). Low SMM was defined as a SMI <7·26 kg m⁻², or ASM% <25·72%. Five-year all-cause mortality risk was calculated using the Calibre 5-year all-cause mortality risk score.

Results Sixty patients were assessed. Thirteen (21-7%) had low SMM. SMI and ASM% correlated positively with VO2peak (r = 0·431 and 0·473, respectively; P<0·001 for both). SMI and ASM% predicted 16·3% and 12·9% of the variance in VO2peak, respectively. SMI correlated most closely with peak oxygen pulse (r = 0·58; P<0·001). SMI predicted 40·3% of peak VO2/HR variance. ASM% was inversely associated with 5-year all-cause mortality risk (r = -0·365; P = 0·006).

Conclusion Skeletal muscle mass was positively correlated with VO2peak in patients with CHD. Peak oxygen pulse had the strongest association with SMM. Low ASM% was associated with a higher risk of all-cause mortality. The effects of exercise and nutritional strategies aimed at improving SMM and function in CHD patients should be investigated.

Introduction

Peak oxygen uptake (VO2peak), measured by a maximal cardiopulmonary exercise test (CPET) represents the upper limit of aerobic capacity. A low VO2peak is associated with the loss of independence in older individuals (Shephard, 2009) and increased all-cause and cardiovascular mortality in patients with coronary heart disease (CHD) (Keteyian et al., 2008). The physiological factors that limit VO2peak are summarized by the Fick equation (Bassett & Howley, 2000; Poole et al., 2012; Lundby et al., 2017):

\[ \text{VO2}_{\text{peak}} = \text{cardiac output} \times (a - \text{vO}_2 \text{ diff}) \]

Where cardiac output is the product of heart rate (HR) and stroke volume (SV), and \( a - vO_2 \text{ diff} \) is the difference between arterial and venous O2 content, representing muscle O2 extraction. In healthy individuals, VO2peak is limited centrally; maximum cardiac output limits O2 delivery to the exercising muscle at the rate that it is required for aerobic resynthesis of ATP (Bassett & Howley, 2000; Lundby et al., 2017). However, in patients with chronic heart failure (CHF), a cascade of events alters peripheral muscle physiology. These include, reduced skeletal muscle oxidative enzyme activity, reduced mitochondrial density, decreased perfusion matching with oxidative muscle fibres (Poole et al., 2012) and decreased skeletal muscle mass (Cicoira et al., 2001). Consequently, the
Peripheral muscle may become the primary limitation to VO\textsubscript{2peak} (Clark et al., 1996; Shelton et al., 2010; Poole et al., 2012).

As CHF worsens, skeletal muscle mass (Collamati et al., 2016) and VO\textsubscript{2peak} decline (Piepoli et al., 2006; Füllster et al., 2013). However, this relationship has not yet been reported in patients with CHD. Around a quarter of patients with CHD have low muscle mass and function (sarcopenia) (Harada et al., 2016), compared with only 10% of adults older than 60 years (Shafee et al., 2017). Patients with CHD are commonly physically inactive which, together with progression of the underlying CHD, may exacerbate loss of muscle mass. Patients with CHD who experience a marked loss of skeletal muscle mass may have a reduced VO\textsubscript{2peak} and consequently higher risk of early mortality. Identifying the relationship between skeletal muscle mass and VO\textsubscript{2peak} in patients with CHD may be important so that preventative exercise and nutritional interventions can be developed.

We aimed to describe the association between skeletal muscle mass and VO\textsubscript{2peak} in male patients with CHD. We also assessed the relationship between skeletal muscle mass and other potentially important variables: peak oxygen pulse (peak VO\textsubscript{2}/HR) (Laukkanen et al., 2006), ventilatory anaerobic threshold (VAT) (Gitt et al., 2002), VE/\textit{VCO}_2 slope (Van de Veire et al., 2006), N-terminal pro B-type Natriuretic Peptide (NT-proBNP) (Omland et al., 2007) and CALIBER 5-year all-cause mortality risk (Rapsomaniki et al., 2014).

**Methods**

**Study design**

Data for this cross-sectional study included baseline measurements taken from male patients enrolled in the Cardiovascular and cardiorespiratory Adaptations to Routine Exercise-based Cardiac Rehabilitation (CARE CR) study (Nichols et al., 2018). Ethical approval was obtained from the Humber Bridge NHS Research Ethics Committee – Yorkshire and the Humber (13/YH/0278). Study procedures conform to the declaration of Helsinki 1964.

The study protocol for CARE CR has previously been reported (Nichols et al., 2018). Briefly, clinically stable male patients who had recently been discharged from hospital following an admission for stable angina, myocardial infarction (MI), coronary artery bypass graft (CABG) surgery or elective percutaneous coronary intervention (PCI) were recruited. Patients were asked to attend the research laboratory having not participated in strenuous exercise within the previous 24 h. Written informed consent was obtained prior to conducting any investigations.

**Resting measurements**

Resting HR and left arm brachial blood pressure were taken at the end of 15 min semi-supine rest using a 12-lead ECG (GE Healthcare, Buckinghamshire, UK) and an ECG-gated automated blood pressure cuff (Tango, SunTech Medical, Eynsham, UK). Stature (cm) was measured using a Leicester Height Measure (SECA, Birmingham, UK). Waist circumference measurements were taken 1 cm above the iliac crest, and hip measurements were taken from the widest aspect of the buttocks. Both measurements were recorded in cm, and the ratio of the two was calculated to determine waist-to-hip circumference ratio (ACSM 2017).

A 2D echocardiogram was used to determine left ventricular (LV) function. LV ejection fraction (LVEF) was calculated using Simpson’s method from measurements of end-diastolic and end-systolic volumes on apical four-chamber and two-chamber 2D views, following the guidelines of Lang and colleagues (Lang et al., 2015). LV systolic dysfunction was diagnosed if LVEF was ≤45%.

**Body composition**

Body composition was determined using dual X-ray absorptiometry [DEXA] (Lunar iDXA, 255 GE Healthcare). Total body mass (kg), lean body mass (kg) and total fat (%) were determined using the Lunar iDXA’s integrated software. BMI (kg m\textsuperscript{-2}) was calculated using DEXA-derived total body mass. Appendicular lean mass (ALM; total lean mass in both arms and legs) was calculated (kg) and indexed to derive skeletal muscle index (SMI; measured in kg m\textsuperscript{-2}). ALM was also reported as a percentage of total body mass (appendicular skeletal mass; ASM%). Low skeletal muscle mass was defined as an SMI of <7.26 kg m\textsuperscript{-2} as recommended by international consensus guidelines (Cruz-Jentoft et al., 2010). A low ASM% was defined as <25.72% (Levine & Crimmins, 2012). This approach may be more appropriate for patients who are overweight/obese and have a higher absolute skeletal muscle mass, but low skeletal muscle mass relative to their total body mass.

**Maximal cardiopulmonary exercise test**

The cardiopulmonary exercise testing adhered to established guidelines and recommendations (American Thoracic Society/American College of Chest Physicians 2003; Balady et al., 2010; Nichols et al., 2015; Taylor et al., 2015) and was performed using the modified Bruce treadmill protocol (Bruce et al., 1973) (GE Healthcare). A 12-lead ECG was monitored continuously throughout the test. An ECG-gated automated BP measurement was recorded at the start of the test and at the second minute of each test stage until the end of the test. Rating of perceived exertion (RPE) scores (6-20) was recorded at peak exercise (Borg, 1982). Breath-by-breath metabolic gas exchange data were collected using an Oxycron Pro metabolic cart (Jaeger, Hoechburg, Germany). VO\textsubscript{2peak} was defined as the mean VO\textsubscript{2} (ml) over the last 30 s of the test. VO\textsubscript{2peak} was also adjusted for body mass (ml kg\textsuperscript{-1} min\textsuperscript{-1}). The VAT was analysed by two independent investigators using the V-slope method (Beaver et al., 1986) with data averaged over the middle five of seven consecutive breaths. The VAT was reported...
in ml, and standardized to patient body mass (ml kg\(^{-1}\) min\(^{-1}\)). \(\text{VO}_2/\text{HR}\) (ml per beat) and VE/\(\text{VCO}_2\) slope were calculated as previously described (Nichols et al., 2015, 2018).

**Pulse wave velocity**

Pulse wave velocity (PWV) between the brachium and ankle was measured (Vascular Explorer, Enverdis GmbH, Düsseldorf, Germany) after 15 min of semi-supine rest (torso elevated 45\(^\circ\)) in a quiet temperature controlled room (21\(^\circ\)C). A blood pressure cuff was placed proximally to the left cubital fossa (brachial artery) and another placed proximally to the medial malleolus. Photoplethysmographic sensors were placed on the patients left index finger and left hallux. Oscillations in the pulse waves alter the volume of the blood pressure cuff and are converted to a PWV. A shorter PWV (ms) indicates more severe arterial stiffness and/or worse peripheral vascular health. The reproducibility of PWV measurement at a single time point has been shown to be good (intraclass correlation 0.72–0.86) (Sutton-Tyrrell et al., 2001).

**Blood samples**

Resting venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA), potassium oxalate and serum separating tubes (SST). EDTA and potassium oxalate tubes were spun in a refrigerated (4\(^\circ\)C) centrifuge at 3000 revolutions per min, for 15 min immediately after the blood draw. Samples collected in SST tubes were allowed to clot for 30 min prior to being centrifuged under the same conditions. Haematocrit and haemoglobin concentrations, neutrophil and lymphocyte count, and NT-proBNP were analysed using a registered National Health Service (NHS) pathology laboratory (Castle Hill Hospital, Hull). All samples not analysed on the day of collection were stored in a −80°C freezer. The ABX Pentra 400 biochemistry auto analyser (Horiba, Montpellier, France) was used to analyse serum plasma glucose, and high sensitivity C-reactive protein (hs-CRP) in duplicate. Calibration and quality controls were conducted in accordance with manufacturer’s guidelines.

**Prognosis – Calibre 5-year all-cause mortality risk**

Five-year risk of all-cause mortality was calculated for each patient using the comprehensive online (https://www.caliber.org/model) Calibre 5-year risk score (Rapsomaniki et al., 2014). The Calibre risk score has been developed in a population of 100 000 patients with CHD. The model has good calibration and discrimination in internal and external validation (C-Index 0.811) for all-cause mortality. Importantly, the model does not include any fitness measurements in its calculation. Five-year risk of all-cause mortality was reported as a percentage. The variables included in the Calibre score are shown in Table 1.

**Statistical analysis**

Statistical analysis was performed using SPSS version 22 (IBM, New York, NY, USA). The distribution of the data were assessed visually and using the Shapiro–Wilk test. Categorical data are reported as percentages. Continuous normally distributed variables are displayed as mean with 95% confidence intervals (95% CI) or standard deviation (±) where specified. Non-normally distributed data are displayed as median (range). Pearson’s (normally distributed), Spearman’s correlations (non-normally distributed) and age-adjusted partial correlations were used to assess the relationship between indices of skeletal muscle mass and variables of interest. An r value of <0.25, 0.26–0.50, 0.51–0.75, and, >0.75 were considered weak, moderate, fair and strong associations, respectively (Berg & Lati, 2008). Scatter plots of partial correlations were constructed using the residuals of the independent skeletal muscle indices and dependent variables. Where a variable was significantly associated with SMI or ASM\%, receiver operating characteristic (ROC) curves were used to investigate the sensitivity and specificity of predicting low skeletal muscle mass. Patients with a low skeletal muscle mass (SMI <7.26 Kg m\(^{-2}\) or ASM% <25-72%) were treated as the dichotomous ‘state-variable’ for the ROC curve. Statistical significance was set at \(P = 0.05\).

Up to six dependent variables with the strongest, significant age-adjusted partial correlations were selected for inclusion within separate stepwise multivariate regression models. The main outcome variables selected were \(\text{VO}_2/\text{HR}\), VAT, peak \(\text{VO}_2/\text{HR}\), CPET duration, Calibre 5-year all-cause mortality risk and NT-proBNP.

**Results**

Sixty male patients (aged, 62.1 ± 10.0 years; BMI, 28.8 ± 3.7 kg m\(^{-2}\)) were recruited. Patient characteristics, comorbidities and medications are reported in Tables 2, 3 and 4, respectively. Fifteen patients (25%) had sustained a ST-elevation MI, 19 (31-7%) a non-ST-elevation MI, 16 (26-7%) underwent elective PCI, 6 (10-0%) CABG and 4 (6-7%) had exertional angina. Comorbidities are shown in Table 3. Median time from cardiac event to baseline assessment was 54 days (range 22–220 days). Mean resting HR was 82 bpm ± 14 bpm. Mean resting systolic and diastolic blood pressure was 127 ± 17 mmHg and 58 ± 9 mmHg, respectively. Four patients (6-6%) had a LVEF <45%, ten (16-7%) had an NT-proBNP >400 pg l\(^{-1}\) and one (1-7%) had an NT-proBNP >2000 pg l\(^{-1}\). The proportion of patients with low skeletal muscle mass was 16-7% by SMI and 11-7% by ASM%. However, only four patients had both a low SMI and ASM%, meaning that 13 (21-7%) had a low SMI or ASM%.

Correlations between ALM, SMI, ASM%, and dependent variables of interest are presented in Table 5. The associations between ALM, SMI and \(\text{VO}_2/\text{peak}\) (ml) were \(r = 0.566\) (\(P<0.001\)) and \(r = 0.473\) (\(P<0.001\)), respectively. The
Table 1: Variables included in the CALIBER 5-year risk score.

| Categorical variables                  | Continuous variables         |
|----------------------------------------|------------------------------|
| Sex                                    | Age                          |
| Belongs to most deprived quintile      | Total cholesterol            |
| CAD diagnosis and severity             | HDL                          |
| Interventions (last 6 months)          | Heart rate                   |
| Smoking status                         | Creatinine                   |
| Hypertension/BP lowering medication    | White cell count             |
| Diabetes                               | Haemoglobin                  |
| Heart failure                          |                             |
| Peripheral arterial disease            |                             |
| Atrial fibrillation                    |                             |
| Stroke                                 |                             |
| Chronic renal disease                  |                             |
| COPD                                   |                             |
| Cancer                                 |                             |
| Chronic liver disease                  |                             |
| Depression                             |                             |
| Anxiety                                |                             |

CAD, Coronary Artery Disease; BP, Blood Pressure; COPD, Chronic Obstructive Pulmonary Disease; HDL, High-density Lipoprotein.

Table 2: Patient characteristics.

| Variable                  | Mean (±SD)                  |
|---------------------------|-----------------------------|
| Age (Years)               | 63.1 (10.0)                 |
| BMI (kg m⁻²)              | 28.8 (3.7)                  |
| ALM (kg)                  | 24.8 (4.0)                  |
| SMI (kg m⁻²)              | 8.3 (1.1)                   |
| ASM%                      | 29.1 (2.5)                  |
| Body fat%                 | 35.5 (9.3)                  |
| Waist/Height ratio        | 0.98 (0.06)                 |
| VO₂peak (ml kg⁻¹ min⁻¹)   | 24.0 (5.6)                  |
| VO₂peak (ml)              | 2079.3 (552.6)              |
| VO₂peak Lean (ml kg⁻¹ min⁻¹) | 38.5 (8.3)  |
| VAT (ml kg⁻¹ min⁻¹)       | 17.2 (5.1)                  |
| VAT (ml)                  | 1481.9 (452.4)              |
| VAT Lean (ml kg⁻¹ min⁻¹)  | 27.8 (7.6)                  |
| Peak VO₂/HR (ml per beat) | 15.5 (3.3)                  |
| Peak HR (bpm)             | 134 (20)                    |
| VE/VO₂ slope              | 34.3 (6.0)                  |
| CPET duration (s)         | 826.6 (193.8)               |
| LVEF (%)                  | 54.3 (6.7)                  |
| Calibre 5-year risk (%)   | 8.3 (7.0)                   |
| NT-proBNP (pg l⁻¹)        | 174.5 (114–2735.0)          |
| hs-CRP (mg l⁻¹)           | 2.3 (3.0)                   |
| Glucose (mmol l⁻¹)        | 6.1 (2.0)                   |

BMI, body mass index; ALM, appendicular lean mass; SMI, skeletal muscle index; ASM%, appendicular skeletal mass; VO₂peak, peak oxygen uptake; VAT, ventilatory anaerobic threshold; VO₂/HR, oxygen pulse; HR, heart rate; bpm, beats per minute; VE/VO₂ slope, ventilatory efficiency with respect to carbon dioxide elimination; CPET, cardiopulmonary exercise test; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; hs, high sensitivity.

The strongest associations between indices of skeletal muscle mass and secondary outcome measures were observed between ALM and peak VO₂/HR (r = 0.633; P < 0.001), SMI VO₂/HR (r = 0.575; P < 0.001) and ASM% and VO₂peak [ml kg⁻¹ min⁻¹] (r = 0.431; P < 0.001). CPET variables that were significantly associated with ALM, SMI and ASM% are shown in Fig. 1. ASM% was the only method of characterizing skeletal muscle mass resulting in a significant association with PWV, NT-proBNP and Calibre 5-year all-cause mortality risk.

ROC curve analysis

Receiver operating characteristic curve analysis was conducted on variables that were significantly associated with measurements of SMI or ASM%. The area under the curve (AUC) for each prognostic variable is shown in Table 6. For SMI, peak VO₂/HR had the greatest predictive capacity (AUC = 0.767; P = 0.008). Values <13.3 ml per beat was predictive of a low SMI. When patients with a low SMI or ASM% were combined, peak VO₂/HR AUC was 0.764 (P = 0.004). A peak VO₂/HR <14.3 ml per beat was most predictive of patients with a low SMI or ASM%. Patients with a NT-proBNP >112.5 pg l⁻¹, a Calibre risk score >3.0% or a modified Bruce treadmill duration <17 min 43 s were also more likely to have a low ASM%.

Table 3: Patient comorbidities (Frequency).

| Comorbidity                              | All patients |
|------------------------------------------|--------------|
| Hypertension (%)                         | 27 (45.0)    |
| Diabetes (%)                             | 11 (18.3)    |
| COPD (%)                                 | 2 (3.3)      |
| Hyperlipidaemia (%)                      | 38 (63.3)    |
| Hypothyroidism                           | 5 (9.1)      |
| Previous PCI (%)                         | 13 (21.7)    |
| Previous MI (%)                          | 14 (23.4)    |
| Previous CABG (%)                        | 4 (6.7)      |
| Previous cardiac valve surgery (%)       | 1 (1.7)      |
| Previous CVA (%)                         | 6 (10.0)     |
| Previous Cancer                          | 8 (13.3)     |

COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass graft; CVA, cerebrovascular accident.

Table 4: Patient medications (Frequency).

| Medications                      | All patients |
|----------------------------------|--------------|
| Aspirin (%)                      | 58 (96.7)    |
| Clopidogrel (%)                  | 16 (26.7)    |
| Ticagrelor (%)                   | 33 (55.0)    |
| Beta-Blockers (%)                | 54 (90.0)    |
| ACE Inhibitors (%)               | 38 (63.3)    |
| Statins (%)                      | 57 (95.0)    |
| Diuretics (%)                    | 5 (8.3)      |
| Nitrates (%)                     | 13 (21.7)    |
| GTN (%)                          | 54 (90.0)    |

ACE, angiotensin converting enzyme; GTN, glyceryl trinitrate.
Table 5  Correlation and partial correlations between appendicular lean mass, skeletal muscle index, appendicular skeletal mass and dependent variables.

| Variable                                    | Appendicular lean mass |          |          | Skeletal muscle index |          |          | Appendicular skeletal mass |          |          |
|---------------------------------------------|------------------------|----------|----------|-----------------------|----------|----------|---------------------------|----------|----------|
|                                             | Pearson's corr. (r)    | P-value  | Partial corr. (r) | P-value | Pearson's corr. (r)    | P-value  | Partial corr. (r) | P-value | Pearson's corr. (r)    | P-value  | Partial corr. (r) | P-value |
| \( \text{VO}_{2\text{peak}} \) (ml)        | 0.666                  | 0.001*   | -0.566   | <0.001*               | 0.577    | <0.001*   | 0.473                    | <0.001*  | 0.225                | 0.084    | 0.205                | 0.130   |
| \( \text{VO}_{2\text{peak}} \) (ml kg\(^{-1}\) min\(^{-1}\)) | 0.189                  | 0.148    | -0.007   | 0.962                | 0.196    | 0.134    | 0.042                    | 0.758    | 0.420                | <0.001*  | 0.431                | 0.001*  |
| VAT (ml)                                    | 0.502                  | 0.001*   | -0.360   | 0.006*               | 0.496    | <0.001*   | 0.365                    | 0.006*   | 0.167                | 0.203    | 0.148                | 0.277   |
| VAT (ml kg\(^{-1}\) min\(^{-1}\))         | 0.053                  | 0.686    | -0.092   | 0.502                | 0.127    | 0.333    | 0.009                    | 0.946    | 0.310                | 0.016*   | 0.312                | 0.019*  |
| Peak \( \text{VO}_{2}/\text{HR} \) (ml per beat) | 0.711                  | 0.001*   | -0.633   | <0.001*               | 0.643    | <0.001*   | 0.575                    | <0.001*  | 0.202                | 0.121    | 0.163                | 0.230   |
| Peak HR (bpm)                               | 0.165                  | 0.208    | -0.042   | 0.751                | 0.110    | 0.402    | -0.073                   | 0.581    | 0.076                | 0.565    | 0.026                | 0.845   |
| \( \text{VE}/\text{VCO}_{2} \) slope       | -0.272                 | 0.036*   | -0.078   | 0.566                | 0.206    | 0.114    | -0.047                   | 0.730    | -0.195               | 0.135    | -0.158               | 0.245   |
| CPET duration (s)                           | 0.182                  | 0.165    | 0.014    | 0.920                | 0.137    | 0.297    | 0.068                    | 0.620    | 0.376                | 0.003*   | 0.399                | 0.022*  |
| LVEF (%)                                    | 0.153                  | 0.244    | 0.077    | 0.574                | 0.137    | 0.297    | 0.068                    | 0.620    | 0.076                | 0.566    | 0.055                | 0.698   |
| Calibre 5-year risk (%)                     | -0.426                 | 0.001*   | -0.230   | 0.870                | -0.372   | 0.003*   | -0.224                   | 0.098    | -0.330               | 0.010*   | -0.365               | 0.006*  |
| NT-proBNP (pg l\(^{-1}\))                  | -0.295                 | 0.025*   | 0.155    | 0.254                | -0.253   | 0.056    | -0.131                   | 0.337    | -0.331               | 0.011*   | -0.326               | 0.014*  |
| hs-CRP (mg l\(^{-1}\))                     | -0.092                 | 0.486    | -0.101   | 0.458                | 0.000    | 0.999    | -0.004                   | 0.974    | -0.193               | 0.140    | -0.184               | 0.175   |
| Glucose (mmol l\(^{-1}\))                  | 0.036                  | 0.789    | -0.051   | 0.708                | 0.135    | 0.314    | 0.065                    | 0.634    | -0.223               | 0.093    | -0.242               | 0.073   |
| Body fat (%)                                | 0.149                  | 0.254    | 0.153    | 0.261                | 0.151    | 0.249    | 0.148                    | 0.275    | -0.401               | 0.001*   | -0.406               | 0.002*  |

corr., correlation; \( \text{VO}_{2\text{peak}} \), peak oxygen uptake; VAT, ventilatory anaerobic threshold; \( \text{VO}_{2}/\text{HR} \), oxygen pulse; HR, heart rate; bpm, beats per minute; \( \text{VE}/\text{VCO}_{2} \) slope, ventilatory efficiency with respect to carbon dioxide elimination; CPET, cardiopulmonary exercise test; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; hs, high sensitivity.

*Significant.
*Spearman correlation.
SMI, skeletal muscle index; ASM%, appendicular skeletal mass; \( \dot{V}O_2 \) peak, peak oxygen uptake; \( \dot{V}O_2/HR \), oxygen pulse; VAT, ventilatory anaerobic threshold; CPET, cardiopulmonary exercise test; NT-proBNP, N-terminal pro B-type natriuretic peptide.

*Significant.
mass (ml kg\(^{-1}\) min\(^{-1}\)). 38.8% of VO\(_{2}\)\(_{\text{peak}}\) (ml kg\(^{-1}\) min\(^{-1}\)) and 17.8% of VAT (ml kg\(^{-1}\) min\(^{-1}\)) variance was accounted for by ASM% and age. ASM% alone accounted for 12.9% of VO\(_{2}\)\(_{\text{peak}}\) variance, compared to 6.3% for VAT. Age and ASM% were also independent predictors of NT-proBNP (\(P<0.001\)) with age accounting for 20.5% of NT-proBNP variance and ASM% accounting for 7.2% (combined model; 27.2%). ASM% accounted for 9.4% of total Calibre 5-year all-cause mortality risk score variance (\(P<0.001\)).

**Discussion**

To our knowledge, this is the first study to investigate the relationship between skeletal muscle mass and VO\(_{2}\)\(_{\text{peak}}\) in patients with CHD. We identified that a lower skeletal muscle mass was associated with a lower VO\(_{2}\)\(_{\text{peak}}\), an observation previously reported in patients with CHF (Cicoira et al., 2001). We also investigated the relationship between other important prognostic indicators, including peak VO\(_{2}/HR\). Our data suggest that skeletal muscle mass may be more closely associated with peak VO\(_{2}/HR\), rather than VO\(_{2}\)\(_{\text{peak}}\). Similar to previously reported data in patients with CHD (Harada et al., 2016), we found that more than one-fifth of patients had a low skeletal muscle mass; a higher proportion than reported among adults over the age of 60 years (10%) (Shafiee et al., 2017). A lower skeletal muscle mass was associated with a higher 5-year all-cause mortality risk.

**Peak oxygen uptake**

Sarcopenia and/or a low muscle mass are associated with increased mortality risk (Cawthon et al., 2007) and difficulties performing daily activities (Janssen, 2006). A low VO\(_{2}\)\(_{\text{peak}}\) is also associated with a higher mortality risk (Keteyian et al., 2008) and difficulties performing daily activities (Shephard, 2009). Consistent with data reported on patients with CHF (\(r = 0.46\) to \(r = 0.70\)) (Cicoira et al., 2001; Piepoli et al., 2006), we found that ALM was positively associated with VO\(_{2}\)\(_{\text{peak}}\) (\(r = 0.566\)). Although dependent on the methods used to scale VO\(_{2}\)\(_{\text{peak}}\), this relationship was maintained when ALM was standardized to stature (SMI; \(r = 0.473\)) and body mass (ASM%; \(r = 0.431\)). However, whilst ALM (43.4%), SMI (16.3%) and ASM% (12.9%) were independent predictors of VO\(_{2}\)\(_{\text{peak}}\), we were unable to replicate the same predictive strength (54-65%) reported by Cicoira et al. in non-cachexic patients with CHF. This may be because patients with CHF can have severe skeletal muscle abnormalities (Clark et al., 1996; Vescovo et al., 1996; Piepoli et al., 2010; Poole et al., 2012) that limit exercise tolerance as a consequence of the disease (Shelton et al., 2010). Given that CHD represents an earlier stage of cardiovascular dysfunction than CHF, skeletal muscle abnormalities may occur at an earlier stage of cardiovascular dysfunction. Skeletal muscle mass may therefore play a greater role in limiting VO\(_{2}\)\(_{\text{peak}}\) among patients with CHF, compared with patients who have CHF. Our observation may suggest that adverse changes in skeletal muscle mass and quality associated with cardiovascular dysfunction exist on a continuum. If this were true, early optimization strategies that target peripheral muscle in addition to cardiac function may be important for disease prevention.

Peak VO\(_{2}/HR\) was most closely associated with indices of skeletal muscle mass. ALM and SMI separately accounted for 49.8% and 40.2% of the variance in peak VO\(_{2}/HR\), respectively. These indices of skeletal muscle mass not only had a stronger association with peak VO\(_{2}/HR\) (\(r = 0.575\) to \(r = 0.633\)) compared to VO\(_{2}\)\(_{\text{peak}}\) (\(r = 0.566\)), but also had the largest AUC (0.767; 95% CI 0.613–0.921; \(P = 0.008\)). Unlike VO\(_{2}\)\(_{\text{peak}}\), peak VO\(_{2}/HR\) had good sensitivity and specificity for detecting patients with a low SMI. A threshold of 13-3 ml per beat was identified as the point below which, patients were more likely to have a low SMI (7.26 kg m\(^{-2}\)). Simple rearrangement of the Fick equation means that peak VO\(_{2}/HR\) becomes independent of HR; a factor that we (\(r = -0.042\), \(-0.073\), 0.026; \(P=0.05\) for all) and others (Horwich et al., 2009; Piepoli et al., 2017) have found to be unrelated to skeletal muscle. Instead, reported peak VO\(_{2}/HR\) characterizes SV and a-vO\(_{2}\) difference (peripheral O\(_{2}\) extraction) which may explain why it appears to be more closely related to skeletal muscle mass than VO\(_{2}\)\(_{\text{peak}}\), in patients with CHD. However, whilst skeletal muscle mass has previously been identified as an independent predictor of peak VO\(_{2}/HR\) (74%) in hypertensive men and women (Lim et al., 2005), the association between peak indices of skeletal muscle mass and peak VO\(_{2}/HR\) in our study was smaller [40.3–49.8%] (Lim et al., 2005). Nonetheless, this is an interesting finding and should be further explored in a larger cohort.

The weaker relationship between indices of skeletal muscle mass and peak VO\(_{2}/HR\) observed in our study may indicate that patients with CHD have a different physiological response to maximal exercise, compared to patients with hypertension. Under normal circumstances, VO\(_{2}/HR\) rises progressively throughout an incremental exercise test until it reaches a plateau associated with normal physiological limitation to exercise (Whipp et al., 1996). However, in patients with CHD, VO\(_{2}/HR\) may prematurely decrease during incremental exercise due to ischaemia-induced myocardial wall-motion abnormalities which cause a reduction in SV (Belardinelli et al., 2003). This is thought to occur prior to ST-segment changes detected using electrocardiogram, or symptoms of angina (Nesto & Kowalchuk, 1987). If myocardial blood flow is not restored through surgical or medical intervention, VO\(_{2}/HR\) would be lower than expected at peak exercise and may attenuate the association between VO\(_{2}/HR\), a-vO\(_{2}\) difference and skeletal muscle mass. Alternatively, a low peak VO\(_{2}/HR\) may indicate greater cardiac dysfunction and consequently, more severe skeletal muscle abnormalities. However, whilst we cannot confirm either of these scenarios, peak VO\(_{2}/HR\) was a better predictor of SMI than any other measured variable, including VO\(_{2}\)\(_{\text{peak}}\), the gold-standard measurement of aerobic exercise capacity. Formal screening for sarcopenia in patients...
who are incidentally found to have a low peak $\text{VO}_2/\text{HR}$ may be beneficial.

**Prognostically important associations with skeletal muscle mass**

Although SMI was associated with peak $\text{VO}_2/\text{HR}$, ASM% was not. However, ASM% was inversely associated with prognostically important variables including; $\text{VO}_2\text{peak}$, PWV, 5-year all-cause mortality risk, a higher NT-proBNP and, body fat percentage even when controlling for age. Although not specifically investigated by our study, the faster PWV speeds observed among patients with a lower SMI indicates more severe arterial stiffness and greater abnormalities in peripheral cardiovascular health, something reported among patients with CHF (Poole et al., 2012). Furthermore, the higher NT-proBNP values reported among patients with a lower ASM% suggests more advanced CHD, or the early development of CHF which may exacerbate the loss of skeletal muscle mass (Collamati et al., 2016). The association between higher body fat percentage and relative lower skeletal muscle mass may also indicate the onset of sarcopenic obesity, fat infiltration of skeletal muscle and therefore reduced muscle quality (Narici & Maffulli, 2010).

**Strengths and weaknesses**

This is the first study to use gold-standard measurement techniques (DXA and CPET) to investigate the relationship between low skeletal muscle mass and reduced aerobic exercise capacity in CHD patients. In addition, this study included a representative cohort of male patients with CHD and the statistical methods employed controlled for several variables that are commonly associated with reduced skeletal muscle mass and aerobic exercise capacity. However, this study has limitations; first, we did not assess muscle function, which meant that we could not report the prevalence of sarcopenia in our cohort. Second, our findings in our male only cohort may not be relevant to females with CHD. In addition, the sample size used in this population was relatively small. Finally, whilst the associations identified in our cross-sectional cohort study are interesting, a prospective long-term follow-up study is required. This would help to determine whether progression of CHD confers with reduced skeletal muscle mass and whether this relates to prognostically important variables and/or the development of CHF.

**Conclusion**

We found a high incidence of low skeletal muscle mass in our cohort of patients with CHD. When standardized to body mass (ASM%), low skeletal muscle mass conferred a higher predicted risk of all-cause mortality. Low skeletal muscle mass was associated with a low $\text{VO}_2\text{peak}$ in patients with CHD; however, the relationship was complex and dependent on the method used to scale skeletal muscle mass and $\text{VO}_2\text{peak}$. Interestingly, our data show that there was a stronger association between SMI and peak $\text{VO}_2/\text{HR}$. The relationship between low skeletal muscle mass, prognostic indices and aerobic fitness suggests that adverse changes in skeletal muscle mass may be initiated before the diagnosis or development of CHF. These findings may highlight a need for preventative exercise and nutritional strategies to improve skeletal muscle mass and quality in patients with CHD.

**Acknowledgments**

We would like to thank Toni Goodman, Wendy Summer, Lesley Richardson and Emma Smith for their help during patient recruitment. We would also like to acknowledge the support of the Hull and East Riding Cardiac Trust Fund who provided financial support which enabled us to analyse our blood samples.

**Funding**

Financial support for blood sample analysis was provided by the Hull and East Riding Cardiac Trust Fund (Hull, East Yorkshire, UK). Funding for a research post (SN) was supported by City Health Care Partnership CIC (Hull, UK). [No Grant Numbers Issued].

**Conflict of interest**

SN received salary match-funding from City Health Care Partnership CIC (Hull, UK) during the data collection period of this study. The authors declare no other conflict of interest.

**Author contributions**

SN contributed to project conception and design, acquisition, analysis and interpretation of data, drafted and critically revised the manuscript. AFO’D contributed to analysis and interpretation of data, and drafted and critically revised the manuscript. CT contributed to the acquisition of data and critically revised the manuscript. ALC contributed to project design and critically revised the manuscript. SC and LI contributed to project conception and design, analysis and interpretation of data, drafted and critically revised the manuscript. All authors have given their final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

**Manuscript status**

We confirm that this manuscript is not under review with any other Journal. This manuscript has not previously been submitted or reviewed by another Journal. Findings reported in this manuscript have not been presented at any conference.
References

ACSM. ACSM’s Guidelines for Exercise Testing and Prescription (2017). Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia.

American Thoracic Society/American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003); 167: 211.

Balady GJ, Arena R, Sisterna K, et al. Clinician’s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation (2010); 122: 191–225.

Bassett D, Howley E. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc (2000); 32: 20–84.

Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol (1986); 60: 2020–2027.

Belardinelli R, Lacalaprice F, Carle F, et al. Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J (2003); 24: 1304–1313.

Berg KE, Latino RW. Essentials of Research Methods in Health, Physical Education, Exercise Science, and Recreation (2008). Lippincott Williams & Wilkins, Philadelphia.

Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982); 14: 377–381.

Bruce RA, Kusum F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J (1973); 85: 546–562.

Cawthon PM, Marshall LM, Michael Y, et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007); 55: 1216–1223.

Cicero AF, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol (2001); 37: 2080–2085.

Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol (1996); 28: 1092–1102.

Collamati A, Marzetti E, Calvani R, et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol (2016); 13: 615–624.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis report of the European Working Group on sarcopenia in older people. Age Ageing (2010); 39: 412–423.

Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2013); 34: 512–519.

Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation (2002); 106: 3079–3084.

Harada H, Imai H, Niyama H, et al. Effectiveness of cardiac rehabilitation for prevention and treatment of sarcopenia in patients with cardiovascular disease—A retrospective cross-sectional analysis. J Nutr Health Aging (2017); 21(4): 449–456. doi: 10.1007/s12603-016-0743-9.

Horwich TB, Leifer ES, Brawner CA, et al. The relationship between body mass index and cardiopulmonary exercise testing in chronic systolic heart failure. Am Heart J (2009); 158: S31–S36.

Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc (2006); 54: 56–62.

Keteyian SJ, Brawner CA, Savage PD, et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J (2008); 156: 292–300.

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr (2015); 28: 1–39.e14.

Laukkanen JA, Kurl S, Salonen JT, et al. Peak oxygen pulse during exercise as a predictor for coronary heart disease and all cause death. Heart (2006); 92: 1219–1224.

Levine ME, Crimmins EM. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. Obesity (Silver Spring) (2012); 20: 2101–2106.

Lim JG, McAvaney TJ, Fleg JL, et al. Oxygen pulse during exercise is related to resting systolic and diastolic left ventricular function in older persons with mild hypertension. Am Heart J (2005); 150: 941–946.

Lundby C, Montero D, Joyner M. Biology of VO2max: looking under the physiology lamp. Am J Physiol (2017); 220: 218–228.

Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull (2010); 95: 139–159.

Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol (1987); 59: C23–C30.

Nichols S, Taylor C, Ingle L. A clinician’s guide to cardiopulmonary exercise testing 2: test interpretation. Br J Hosp Med (2015); 76: 281–289.

Nichols S, Nation F, Goodman T, et al. CARE CR-Cardiovascular and cardiorespiratory adaptations to routine exercise-based cardiac rehabilitation: a study protocol for a community-based controlled study with criterion methods. BMJ Open (2018); 8: e019216.

Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007); 50: 205–214.

Piepoli MF, Kaczmarek A, Francis DP, et al. Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation (2006); 114: 126–134.

Piepoli MF, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. Eur J Cardiovasc Prev Rehabil (2010); 17: 643–648.

Piepoli MF, Corra U, Agostoni P. Cardiopulmonary exercise testing in patients with heart failure with specific comorbidities. Am Am Thorac Soc (2017); 14: S110–S115.

Poole DC, Hirai DM, Copp SW, et al. Muscle oxygen transport and utilization in heart failure: implications for exercise (in) tolerance. Am J Physiol Heart Circ Physiol (2012); 302: H1050–H1063.

Rapsomaniki E, Shah A, Perel P, et al. Prognostic models for stable coronary artery disease based on electronic health record cohort of 102,023 patients. Eur Heart J (2014); 35: 844–852.

Shafiee G, Keshkak A, Soltan A, et al. Preva- lence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord (2017); 16: 21.

Shelton RJ, Ingle L, Rigby AS, et al. Cardiac output does not limit submaximal exercise capacity in patients with chronic heart failure. Eur J Heart Fail (2010); 12: 983–989.

Shephard RJ. Maximal oxygen intake and independence in old age. Br J Sports Med (2009); 43: 342–346.

Sutton-Tyrrell K, Mackey RH, Holubkov R, et al. Measurement variation of aortic pulse wave velocity in the elderly. Am J Hypertens (2001); 14: 463–468.

Taylor C, Nichols S, Ingle L. A clinician’s guide to cardiopulmonary exercise testing...
Van de Veire NR, Van Laethem C, Philippé J, et al. VE/Vco2 slope and oxygen uptake efficiency slope in patients with coronary artery disease and intermediate peakVo2.

Eur J Cardiovasc Prev Rehabil (2006); 13: 916–923.

Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microiopsies by high resolution electrophoresis. Heart (1996); 76: 337–343.

Whipp BJ, Higgenbotham MB, Cobb FC. Estimating exercise stroke volume from asymptotic oxygen pulse in humans. J Appl Physiol (1996); 81: 2674–2679.